Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
P/E ratio for Trevi Therapeutics, Inc. (TRVI)
P/E ratio as of 2023: -4.57
According to Trevi Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.57. At the end of 2022 the company had a P/E ratio of -4.27.
P/E ratio history for Trevi Therapeutics, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.57 |
| 2022 | -4.27 |
| 2021 | -0.53 |
| 2020 | -1.33 |
| 2019 | -1.69 |
| 2018 | -3.44 |
| 2017 | -5.50 |
| 2016 | -11.48 |